Exicure (XCUR) Change in Accured Expenses (2016 - 2026)
Exicure (XCUR) reported Change in Accured Expenses of -$400000.0 for Q1 2026, down 226.58% on a YoY basis from $316000.0 in Q1 2025, and down 1718.18% quarter-over-quarter from -$22000.0 in Q4 2025.
Exicure (XCUR) Change in Accured Expenses (2016 - 2026) Analysis & Trends
Exicure has reported Change in Accured Expenses for 11 years, with the latest figure at -$400000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses fell 226.58% year-over-year to -$400000.0; the trailing twelve-month figure through Mar 2026 stood at -$1.3 million (down 322.22% YoY), and the FY2025 full-year result was -$614000.0, up 25.76% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$400000.0, down from -$22000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $2.7 million in Q3 2022, with the low at -$4.7 million in Q4 2022.
- Historically, Change in Accured Expenses has averaged -$436823.5 across 5 years, with a median of -$196000.0 in 2024.
- The largest YoY upside for Change in Accured Expenses was 1953.1% in 2022 against a maximum downside of 3108.84% in 2022.
- Exicure's Change in Accured Expenses stood at -$4.7 million in 2022, then soared by 102.9% to $137000.0 in 2023, then tumbled by 259.12% to -$218000.0 in 2024, then surged by 89.91% to -$22000.0 in 2025, then slumped by 1718.18% to -$400000.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$400000.0 (Q1 2026), -$22000.0 (Q4 2025), and -$698000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Accured Exp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 931,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Exicure | 19.38 Mn | 16.77 Mn | - | -400,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -400,000.00 |
| Mar 31, 2026 | -400,000.00 |
| Dec 31, 2025 | -22,000.00 |
| Dec 31, 2025 | -22,000.00 |
| Sep 30, 2025 | -698,000.00 |
| Sep 30, 2025 | -698,000.00 |
| Jun 30, 2025 | -210,000.00 |
| Jun 30, 2025 | -210,000.00 |
| Mar 31, 2025 | 316,000.00 |
| Mar 31, 2025 | 316,000.00 |
| Dec 31, 2024 | -218,000.00 |
| Dec 31, 2024 | -218,000.00 |
| Sep 30, 2024 | -577,000.00 |
| Sep 30, 2024 | -577,000.00 |
| Jun 30, 2024 | 164,000.00 |
| Jun 30, 2024 | 164,000.00 |
| Mar 31, 2024 | -196,000.00 |
| Mar 31, 2024 | -196,000.00 |
| Dec 31, 2023 | 137,000.00 |
| Dec 31, 2023 | 137,000.00 |